Biomarin Pharmaceutical Inc (BMRN)

Jun 18, 2025

BioMarin Generates Patient Experience Data With Early And Often Engagement - Clinical Leader

Jun 18, 2025

Jun 15, 2025

Jim Cramer on BioMarin: “I Don’t Think It Works Now” - MSN

Jun 15, 2025

Jun 14, 2025

BioMarin’s SWOT analysis: stock growth potential amid rare disease focus - Investing.com

Jun 14, 2025

Jun 13, 2025

BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz - MSN

Jun 13, 2025

Jun 12, 2025

Jim Cramer Discussed These 16 Stocks Recently - Insider Monkey

Jun 12, 2025

Jun 12, 2025

Phenylktonuria Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Erytech Pharma SA, Homology Medicines Inc., Synlogic Inc., BioMarin Pharmaceuticals - Barchart.com

Jun 12, 2025

Jun 12, 2025

Jim Cramer Is All Aboard Union Pacific, But Shows No Love For Orphan Drugs - Benzinga

Jun 12, 2025

Jun 09, 2025

Morquio Syndrome (MPS-IV) Drug Market Is Booming So Rapidly - openPR.com

Jun 09, 2025

Jun 05, 2025

Here Are All 6 Stocks I've Bought Through 5 Months of 2025 - The Motley Fool

Jun 05, 2025

Jun 05, 2025

The Top 12 Companies Hiring in Biopharma Now - BioSpace

Jun 05, 2025

Jun 04, 2025

Marin Awareness Walk Draws Over 100 Community Members - Patch

Jun 04, 2025

Jun 02, 2025

inozyme pharma announces executive bonuses amid merger plans By Investing.com - Investing.com Nigeria

Jun 02, 2025

Jun 02, 2025

inozyme pharma announces executive bonuses amid merger plans - Investing.com

Jun 02, 2025

May 30, 2025

BioMarin Now Targets $3 Bln Revenue Goal For 2025 - RTTNews

May 30, 2025

May 30, 2025

The past five years for BioMarin Pharmaceutical (NASDAQ:BMRN) investors has not been profitable - simplywall.st

May 30, 2025

May 29, 2025

Is the Options Market Predicting a Spike in BioMarin Pharmaceutical Stock? - MSN

May 29, 2025

May 28, 2025

Is The Options Market Predicting A Spike In BioMarin Pharmaceutical Stock? - Barchart.com

May 28, 2025

May 28, 2025

Noonan Syndrome Market Growth to Accelerate in Forecast Period (2023-2032), DelveInsight Analyzes | Novo Nordisk A/S, BioMarin Pharma - The Globe and Mail

May 28, 2025

May 27, 2025

FDA issues BioMarin complete response letter for Duchenne muscular dystrophy drug Kyndrisa - FirstWord Pharma

May 27, 2025

May 27, 2025

Stifel maintains Buy on BioMarin, price target at $91 By Investing.com - Investing.com India

May 27, 2025

May 27, 2025

Stifel maintains Buy on BioMarin, price target at $91 - Investing.com

May 27, 2025

May 26, 2025

Phenylktonuria Treatment Market Overall Study Report - openPR.com

May 26, 2025

May 26, 2025

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock - Yahoo Finance

May 26, 2025

May 25, 2025

BioMarin’s SWOT analysis: genetic medicine firm’s stock shows growth potential - Investing.com

May 25, 2025

May 24, 2025

Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More - MSN

May 24, 2025

May 24, 2025

Inozyme Stock Rockets 179% After BioMarin Agrees To Acquire The Company For $270M: Retail Sentiment Brightens - MSN

May 24, 2025

May 23, 2025

Rx Rundown: BioMarin, Novavax, CellCentric and more - Medical Marketing and Media

May 23, 2025

May 22, 2025

BioMarin Pharmaceutical Approves Equity Plan Amendment - TipRanks

May 22, 2025

May 22, 2025

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio - Yahoo

May 22, 2025

May 22, 2025

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), ACADIA Pharmaceuticals (ACAD) and Quanterix (QTRX) - The Globe and Mail

May 22, 2025

May 21, 2025

BioMarin’s Acquisition of Inozyme Pharma - Global Legal Chronicle

May 21, 2025

May 21, 2025

INOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc.INZY - Business Wire

May 21, 2025

May 21, 2025

6,941 Shares in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Acquired by Focus Partners Wealth - Defense World

May 21, 2025

May 21, 2025

BioMarin agrees to acquire Inozyme for $270m - MSN

May 21, 2025

May 20, 2025

Insider Sell Alert: Erin Burkhart Sells Shares of Biomarin Pharmaceutical Inc (BMRN) - GuruFocus

May 20, 2025

May 19, 2025

Is this European biotech’s moment? — a BioCentury podcast - biocentury.com

May 19, 2025

May 19, 2025

BioMarin Expands Rare Disease Portfolio with $270M Inozyme Acquisition - MSN

May 19, 2025

May 19, 2025

BioMarin to buy enzyme therapy developer Inozyme in $270M all-cash deal - MSN

May 19, 2025

May 19, 2025

Inozyme Pharma finds buyer in BioMarin after strategic review - The Business Journals

May 19, 2025

May 19, 2025

Bernstein raises BioMarin stock target to $95, maintains Outperform - Investing.com Australia

May 19, 2025

May 19, 2025

Bernstein raises BioMarin stock target to $95, maintains Outperform By Investing.com - Investing.com Nigeria

May 19, 2025

May 19, 2025

BioMarin: Inozyme Acquisition Falls Short Of Offsetting Looming Revenue Risks (Downgrade) - Seeking Alpha

May 19, 2025

May 19, 2025

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Average Rating of “Moderate Buy” by Brokerages - Defense World

May 19, 2025

May 18, 2025

BioMarin Buying Inozyme Pharma In $270 Million Deal - Pulse 2.0

May 18, 2025

May 18, 2025

StockWatch: With Inozyme Buyout, BioMarin Pursues Growth via M&A - Genetic Engineering and Biotechnology News

May 18, 2025